1. Scrip
  2. >>Business
  3. >>Commercial Strategy

Agios CEO Fouse On Building A Sustainable Business Model

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

In the midst of another restructuring, the company is transitioning from a drug discovery company to a more externally focused R&D model; CEO Jackie Fouse talked to Scrip about the changes at Agios.

new direction
Agios is going in a new direction when it comes to early R&D • Source: Shutterstock (Shutterstock)

Having shifted its commercial and research focus from cancer to non-cancer hemolytic rare diseases last year, Agios Pharmaceuticals, Inc. is now paring back on drug discovery research to focus on advancing a later-stage portfolio of drugs, including potentially ones that will be externally sourced. It's a significant change for a company that was initially established in 2008 as a drug discovery company, but CEO Jackie Fouse said it is all part of an evolution to develop a sustainable business model and tap current market opportunities.

Fouse talked to Scrip in an interview on 18 May about the R&D reorganization, how the company hopes to direct...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.